For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| General and administrative costs | 132,030 | 122,096.25 | ||
| Total operating expenses | 132,030 | 122,096.25 | ||
| Loss from operations | -132,030 | -122,096.25* | ||
| Interest earned on cash and investments held in trust account | 4,439,850 | 1,233,450* | ||
| Gain on extinguishment of over-allotment option liability | - | 138,437* | ||
| Provision for credit losses | - | 203,028.25* | ||
| Recovery of credit losses | -30,000 | - | ||
| Total other income | 4,469,850 | 1,168,858.75* | ||
| Net income (loss) | 4,337,820 | 1,046,762.5 | ||
| Basic EPS | 0.07 | 0.079 | ||
| Diluted EPS | 0.07 | 0.079 | ||
| Basic Average Shares | 50,000,000 | 13,287,671 | ||
| Diluted Average Shares | 50,000,000 | 13,287,671 | ||
Drugs Made In America Acquisition II Corp. (DMIIR)
Drugs Made In America Acquisition II Corp. (DMIIR)